Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

Merck to Buy Idenix for $3.9B for Hepatitis C Drugs Play

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

  • On Air Now

    The Pulse Watch Now

  • Next

    Bloomberg Surveillance

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus